Still Standing Strong: A Narrative Review of Why BCG Remains Central to Global Tuberculosis Control
Abstract
Background: Tuberculosis is one of the deadliest infectious diseases in the world. However, the BCG vaccine has shown significant results and remains in use to this day. Objective: This review aims to provide a comprehensive perspective on the resilience of the BCG vaccine over more than a century, as well as its implications for future vaccination strategies. Methods: A narrative review approach was used, employing keywords such as “BCG vaccine,” “tuberculosis immunization,” “trained immunity,” “TB vaccine pipeline,” and “MTBVAC,” “M72/AS01E,” “VPM1002” in databases such as PubMed and Scopus. Conclusion: Considering all scientific, clinical, socio-economic, and systemic factors, it can be concluded that to date, no new TB vaccine candidate has a comprehensive profile that significantly surpasses BCG. Therefore, BCG remains the most viable and reliable intervention in the context of global TB prevention, at least until new vaccines with high efficacy, long-term safety, and readiness for global implementation are successfully developed and thoroughly validated. Keywords: BCG Vaccine, Tuberculosis Latar Belakang: Tuberkulosis merupakan sakah satu penyakit infeksi yang mematikan di dunia. Namun, vaksin BCG menunjukan hasil signifikan sehingga masih bertahan sampai saat ini. Tujuan: Tinjauan ini bertujuan memberikan perspektif yang komprehensif mengenai ketahanan vaksin BCG selama lebih dari satu abad, serta implikasinya terhadap strategi vaksinasi di masa depan. Metode:…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.